Please login to the form below

Not currently logged in
Email:
Password:

Dr Holger Adelmann joins DIA EMEA

Succeeds Dr Jytte Lynvig as senior vice president and managing director

Dr Holger AdelmannThe DIA (Drug Information Association) has appointed Dr Holger Adelmann as its new senior vice president and managing director for DIA Europe, Middle East and Africa (EMEA).

Dr Adelmann brings nearly 30 years of clinical pharmacology experience to the role at the Washington, DC-headquartered group.

He joined the industry in 1989 and has previously held leading positions at AstraZeneca, Bayer, Merk Serono and Tropon.

Most recently, Dr Adelmann served as the global head of Merck Serono's clinical pharmacology and clinical biomarker operations in Germany.

In that role he oversaw the reengineering of its clinical biomarker and companion diagnostics business to align with upcoming portfolio demands.

Barbara Lopez Kunz, DIA's global chief executive, said: “Holger's diverse background provides us with the leadership necessary to deliver that trusted, future-oriented knowledge and connect the global health care community to this rapidly evolving region.”

Dr Adlemann succeeds Dr Jytte Lynvig who retired from the post earlier this month.

22nd February 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics